Introduction:
The liver stands out as the primary site of metastasis in colorectal cancer patients, mainly due to its relationship with the body's portal circulation. The detection rate increases to 35% when employing computed tomography (CT) scans. Despite advancements in diagnostic and therapeutic approaches over recent decades, the prognosis remains grim for patients with metastases, disease recurrence, or advanced local tumors. Without intervention, median survival is typically less than eight months from presentation, with a five-year survival rate of just 11% for those with localized metastases.
Even for patients with limited metastatic disease, long-term survival is rare, though some cases have shown exceptional outcomes. Advanced surgical techniques, as practiced in leading hepatobiliary centers, have demonstrated the feasibility of hepatectomy involving up to 70% of the liver, with a mortality rate of less than 5%. Understanding predisposing factors, diagnostic modalities, and treatment options for hepatic metastases. However, developing effective preventive screening programs for early detection and optimal management is imperative.
Can Colon Cancer Spread to the Liver?
The spread of tumor cells to the liver, known as hepatic metastasis, is a critical factor in the mortality of cancer patients, particularly those with colorectal cancer. It is essential to recognize that not all liver lesions in patients with a history of colon cancer are metastatic; however, the majority are. Various other mass lesions, such as benign liver cysts, hemangiomas, adenomas, focal nodular hyperplasia, hepatocellular carcinoma, and metastases from other sites, can occur with some frequency. A comprehensive patient history, laboratory, and imaging studies are essential to distinguish between these disorders and colorectal metastases. This combination typically enables an accurate preoperative diagnosis in most cases.
Preoperative biopsy is rarely needed for patients with resectable disease. However, for patients who are not candidates for resection and typically need different chemotherapeutic regimens in adjuvant and metastatic settings, a tissue diagnosis or definitive imaging may be necessary before starting chemotherapy. In such cases, percutaneous biopsy might be appropriate.
What Is the Treatment Outlook for the Spread of Colon Cancer to the Liver?
Systemic and locoregional chemotherapy, along with targeted agents, play pivotal roles in managing colorectal liver metastases (CLM). However, decision-making in this area is intricate and evolving, considering various patient-specific factors and the heterogeneity of treatment contexts.
Chemotherapy-related hepatotoxicity significantly influences treatment decisions and outcomes. It manifests in three primary forms: steatosis, steatohepatitis, and sinusoidal obstruction syndrome (SOS). Steatosis, characterized by fat accumulation in hepatocytes, can progress to steatohepatitis and, ultimately, cirrhosis. Chemotherapeutic agents like 5-Fluorouracil and Irinotecan are associated with these hepatic changes. Additionally, Oxaliptalin is linked to SOS. Chemotherapy duration also impacts perioperative complications, with fewer cycles associated with lower complication rates.
Given its impact, hepatotoxicity influences the choice of chemotherapeutic agents, with caution advised, especially regarding Irinotecan’s reported increased mortality in patients with pre-existing steatosis.
Patients with unresectable liver metastases comprise a heterogeneous group. A multidisciplinary evaluation that considers patient and tumor characteristics is essential. Treatment objectives vary based on patient performance status and symptomatology. Chemotherapy options include combinations of Fluoropyrimidines, Oxaliplatin, Irinotecan, and targeted anti-EGFR or anti-angiogenic agents. Triplet chemotherapy has shown increased median OS but with more significant toxicity.
EGFR blockade combined with chemotherapy improves OS and progression-free survival in colorectal liver metastases. However, its efficacy varies based on mutational status, with RAS mutations rendering tumors insensitive. Primary tumor sidedness also influences responses, with right-sided tumors showing less benefit. Toxicity concerns have limited the combination of EGFR blockade with anti-angiogenic agents.
Various novel agents targeting oncogenic pathways are under investigation. Multi-kinase inhibitors Regorafenib and EGFR pathway blockade using tyrosine kinase inhibitors have shown benefits. Targeting BRAF mutations with Vemurafenib and MEK kinase with Selumetinib has shown tumor response. Immunotherapy with Pembrolizumab has shown promise, particularly in mismatch-repair deficient tumors.
Neoadjuvant chemotherapy in initially resectable liver metastases aims to assess chemo-responsiveness, shrink tumors to increase the chances of R0 resection, and eliminate micro-metastases. However, its advantages must be weighed against potential toxicities. The decision to use neoadjuvant chemotherapy in up-front resectable CRLM is influenced by trial evidence and individual case nuances. Patients may be technically resectable but present poor oncological outcomes. Factors such as tumor burden and patient characteristics are considered in decision-making, often leading to a case-by-case approach.
Adjuvant chemotherapy allows for chemotherapy delivery without the complications associated with neoadjuvant chemotherapy.
Downsizing chemotherapy for initially unresectable CRLM has shown promising results, with high response rates and conversion to resectable status. Chemotherapy regimens based on Oxaliplatin and Irinotecan have achieved similar response and resection rates. Triplet combinations like FOLFOXIRI have demonstrated improved outcomes but with increased toxicity.
EGFR blockade in downsizing settings has improved conversion and resection rates in RAS wild-type patients. Anti-angiogenic therapies like Bevacizumab have also been studied in this context, showing increased resection rates and progression-free survival. The choice between EGFR blockade and anti-angiogenic treatment is complex and influenced by factors like RAS status and primary tumor sidedness.
In addition to systemic agents, locoregional chemotherapy delivered intra-arterially offers an alternative approach. It involves hepatic arterial infusion (HAI) chemotherapy and transarterial delivery of Irinotecaan-coated beads (DEBIRI). HAI chemotherapy capitalizes on the predominantly arterial blood supply to colorectal liver metastases, facilitating high intrahepatic drug concentrations while minimizing systemic exposure. While early reports suggested survival benefits with HAI, particularly with newer agents like Oxaliplatin HAI, subsequent trials reported mixed findings.
DEBIRI involves transarterial delivery of Irinotecan-coated beads, offering prolonged antineoplastic effects. The mechanism of DEBIRI presents a paradox: while administered intra-arterially for a regional effect, Irinotecan requires activation in healthy liver parenchyma to its active form. Clinical experience with DEBIRI has shown promising outcomes, with overall response rates of 56 percent of patients typically having undergone multiple prior chemotherapy lines.
Radiation-based therapies like SIRT and SBRT offer options for treating unresectable colorectal liver metastases. SIRT delivers radioactive microspheres to tumors via the arterial blood supply, but recent trials have not shown an overall survival benefit. SBRT, on the other hand, delivers precise radiation directly to tumors, showing promising outcomes in terms of overall and progression-free survival. However, interpreting SBRT effectiveness is complex due to variations in study populations and techniques, and recruitment to trials can be challenging. More research is needed to clarify SRBT’s role and potential synergies with other treatments.
Hepatic resection is the primary therapy for colorectal liver metastases (CRLM), defined as complete gross removal while retaining sufficient liver function. Anatomical resections are favored for their better margin status and improved survival compared to wedge resections. Portal vein embolization can extend resectability by inducing liver hypertrophy. Survival rates post-resection range from 28 to 50 percent, with low perioperative mortality and morbidity. Despite potential cures, recurrence is standard, with prognostic factors including CEA level, disease-free interval, and tumor characteristics. Recurrent disease often requires re-resection, feasible in 20 to 30 percent of cases with outcomes similar to primary resection. The role of surgery remains pivotal, offering prolonged survival and sometimes a chance for curer, especially when integrated with systemic treatments.
Conclusion:
Advancements in the management of metastatic colorectal cancer in the liver have led to improved outcomes. A multidisciplinary approach, including modern chemotherapy and refined surgical techniques, is critical. Perioperative chemotherapy, especially FOLFOX4, is preferred for resectable metastases, while adjuvant chemotherapy is an option post-surgery. Conversion chemotherapy FOLFIRINOX is used for initially unresectable cases. Palliative chemotherapy, possibly with targeted agents, is standard for unresectable metastases. Further research will define the role of targeted therapy in the neoadjuvant setting. Continued investigation into more effective regimens and innovative techniques is crucial for enhancing outcomes.
